武清区龙济医院电话预约重点龙济男科医院,天津武清区龙济医院治疗男子疾病,天津龙济看泌尿科具体费用,武清男科医院哪里好龙济,天津市龙济医院男科医院可靠吗,天津龙济医院男科医院的电话,天津龙济泌尿外科在哪里

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

WASHINGTON, Jan. 19 (Xinhua) -- New research published this week in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.The study, led by investigators with the Ohio State University Comprehensive Cancer Center, shows that overexpression of two genes called MET and EGFR causes the deregulation of six microRNAs, and that this deregulation leads to gefitinib resistance.The findings support the development of agents that restore the levels of these microRNAs. It offers a new strategy for treating non-small cell lung cancer, which is responsible for about 85 percent of the 221,000 lung-cancer cases and 157,000 deaths that occur annually in the United States. It also suggests that measuring the expression levels of certain microRNAs -- those controlled by the MET gene -- might predict which lung-cancer cases are likely to be resistant to gefitinib.Epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small cell lung cancer, and this leads to uncontrolled cell proliferation. Gefitinib selectively inhibits EGFR activation and triggers cancer cells to self-destruct by apoptosis. However, non-small cell lung cancer cells inevitably develop resistance to the drug. The study reveals how this resistance occurs."Our findings suggest that gefitinib resistance that is caused by MET overexpression is at least partly due to miRNA deregulation, " says principal investigator Carlo Croce.

OTTAWA, Oct. 26 (Xinhua) -- Canadians are working about three years longer before retirement than they were in the 1990s, and have a longer life in retirement, an official study said Wednesday.Statistics Canada, the federal statistics agency, reports that Canada' s men and women, who don't face compulsory retirement, are increasingly choosing to delay retirement, as part of a long-term trend that has begun before the recent recession.The trend of later retirement dates back to the mid-1990s, when a 50-year-old employee could expect to work another 12.5 years before retiring from the daily grind.Today, that same 50-year-old worker could expect another 16 years of employment.The study says that 34 percent of Canadians aged 55 and older were employed in 2010, compared to just 22 percent in 1996.A longer working life would unnecessarily imply a shorter life in retirement due to increased life expectancy, the study says.The study notes that men and women leaving the work force today are spending as much time in their post-career life as many of their predecessors did.For example, between 1977 and 1994, the typical retirement length for a man in Canada rose from 11.2 to 15.4 years; as of 2008, it was 15 years.For women, the average retirement length similarly rose from 16.4 to 20.6 years between 1977 and 1996; as of 2008, it was 19 years.From another point of observation, 50-year-old men can expect to spend 48 percent of their remaining years of life in retirement in 2008,compared with 45 percent in 1977.In 2008, 50-year-old women could expect to spend 55 percent of their remaining years of life in retirement, nearly identical to the proportion in 1977.

BEIJING, Jan. 26 (Xinhua) -- China will firmly stand together with African countries while unswervingly pushing forward Sino-African strategic partnership, no matter how the international environment changes, said Chinese Vice Foreign Minister Zhai Jun Thursday.Zhai made the remarks in a signed article on top Chinese political advisor Jia Qinglin's upcoming visit to Africa.Africa still faced enormous challenges against the backdrop of simmering global finance crisis, and turbulence encountered by several countries in western Asia and northern Africa, which dealt a blow to Africa's peace, stability and development, Zhai said, adding that some outside forces' intervention into Africa's internal affairs impeded the integration process among African countries.Within this context, there is stronger demand of African countries for stability, development, solidarity and independence, he said.The international community should pay more attention to Africa's voice and problems, respect its opinions, accommodate its concerns, protect peace, stability and development in Africa, and support Africa's independent settlement of issues in its own region, Zhai said.He said Jia's visit, first foreign trip paid by Chinese leaders in the Chinese Lunar New Year, will be of great significance in deepening Sino-African ties and cementing the solidarity and cooperation among developing countries, Zhai said.Jia will declare China's determination on developing Sino-African ties during the trip, he said.Enhancing solidarity and cooperation with Africa constitutes an important part of China's diplomacy, and will be the long-term strategic choice firmly pursued by China, Zhai said.

BEIJING, Sept. 29 (Xinhuanet) -- Even a slightly high blood pressure is considered dangerous to largely increase the stroke risk, a new study found.The finding was published Wednesday on the online edition of U.S. medical journal Neurology.In the study, researchers found people who have pre-hypertension, whose blood pressure measured between normal and high, are 55 percent more likely to suffer a stroke compared with normal people.The study involved data from 12 previous studies on blood pressure and stroke occurrence of some 500,000 adults.About one in three U.S. adults suffer from pre-hypertension, which is defined at a systolic blood pressure between 120 and 139 or a diastolic blood pressure between 80 and 89, according to the U.S. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure."People who do fall into the higher range of pre-hypertension should modify their lifestyle as much as possible," suggested Dr. Bruce Ovbiagele, director of the Olive View-UCLA Stroke Program and leading author of the study.Stroke is the number three cause of death, killing more than 130,000 in the U.S. a year, according to a CBS report.